Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Morepen Laboratories announced strong Q4 FY26 results with net profit climbing 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. The company also initiated commercial execution of its CDMO program and proposed a 10% dividend for FY26.
May 27 2026 08:25:48
Morepen Laboratories Limited
Morepen Laboratories has executed a second addendum to its Business Transfer Agreement (BTA) with subsidiary Morepen Medipath Limited. The 'Appointed Date' for the transfer of the undertaking is now revised to April 1, 2026, primarily due to delays in obtaining necessary statutory licenses and regulatory approvals.
May 26 2026 18:12:24
Morepen Laboratories Limited
Morepen Laboratories' board recommended a final dividend of Rs.0.20 per share for FY26. The record date and AGM date for approval will be intimated later.
May 26 2026 18:01:46
Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Morepen Laboratories' Board approved the second addendum to the Business Transfer Agreement (BTA) with subsidiary Morepen Medipath Limited for the slump sale of its Medical Devices business. The transaction is for Rs.197.10 crore, with the revised appointed date for transfer set to April 1, 2026.
May 26 2026 17:56:35
Morepen Laboratories Ltd - 500288 - Corporate Action-Board approves Dividend
Morepen Laboratories Board recommended a final dividend of ₹0.20 per equity share for the financial year ended March 31, 2026. This is subject to shareholder approval at the upcoming Annual General Meeting.
May 26 2026 17:53:34
Morepen Laboratories Ltd - 500288 - Board Meeting Outcome for Board Meeting Outcome For Q4 And FY26 Results
Morepen Laboratories board approved audited consolidated financial results for Q4 FY26, reporting a net profit of ₹15.70 crores. A final dividend of ₹0.20 per equity share was recommended for FY26.
May 26 2026 17:36:47
Morepen Laboratories Limited
Morepen Labs' board meeting, originally on May 22, 2026, has been rescheduled to May 26, 2026. The agenda includes considering audited annual financial results for FY26 and a final dividend.
May 21 2026 19:47:55
Morepen Laboratories Ltd - 500288 - Update on board meeting
Morepen Laboratories' board meeting has been rescheduled to May 26, 2026. The board will consider and approve the audited standalone and consolidated financial results for Q4 and the full financial year ended March 31, 2026, and may recommend a final dividend.
May 21 2026 19:38:02
Morepen Laboratories Limited
Morepen Laboratories transferred 1.62 lakh equity shares of its subsidiary Morepen Medipath Limited (MML) to Mr. Anubhav Suri, Head - Medical Devices Business. This strategic move aims to align Mr. Suri's interests with MML's long-term growth and ensures continuity of leadership, while MML remains a 51% owned subsidiary.
May 20 2026 19:17:47
Morepen Laboratories Limited
Morepen Labs approved the transfer of 1.62 lakh equity shares of its subsidiary Morepen Medipath Ltd to Mr. Anubhav Suri. This strategic move reduces Morepen's stake from 60% to 51% in MML, aiming to align the Head - Medical Device Business's interests with MML's growth while retaining MML as a consolidated subsidiary.
May 20 2026 19:13:01
Read More